← Back to Analyst Consensus 
IPHA Buy
Innate Pharma SA
Current Price —
Implied Upside —
Analysts 7
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 17, 2026 | BTIG | reiterate | Buy → Buy | $9 | 52% |
| Aug 12, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Aug 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 7, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Oct 29, 2025 | HC Wainwright & Co. | upgrade | Neutral → Buy | $5 | 44% |
| Oct 29, 2025 | BTIG | reiterate | Buy → Buy | $8 | 52% |
| Sep 18, 2025 | Leerink Partners | downgrade | Outperform → Market Perform | $2 | 51% |
| Sep 18, 2025 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| Apr 24, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Mar 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Feb 6, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Jan 17, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Dec 9, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Nov 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Nov 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Sep 13, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Jun 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| May 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Apr 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Mar 22, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Nov 15, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Sep 18, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Jun 16, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $11.5 | 44% |
| Mar 24, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $11.5 | 44% |
| Nov 15, 2022 | SVB Leerink | maintain | — → Outperform | $9 | — |
| Sep 16, 2022 | Citigroup | maintain | — → Buy | $12 | 54% |
| Aug 2, 2022 | SVB Leerink | maintain | — → Outperform | $10 | — |
| May 11, 2022 | SVB Leerink | maintain | — → Outperform | $11 | — |
| Sep 17, 2021 | SVB Leerink | maintain | — → Outperform | $9 | — |
| Sep 3, 2021 | SVB Leerink | upgrade | Market Perform → Outperform | $0 | — |
| Sep 2, 2021 | SVB Leerink | upgrade | Market Perform → Outperform | $0 | — |
| Mar 19, 2021 | SVB Leerink | maintain | — → Market Perform | $7 | — |
| Dec 15, 2020 | SVB Leerink | downgrade | Outperform → Market Perform | $5 | — |
| Dec 14, 2020 | HC Wainwright & Co. | maintain | — → Buy | $11.5 | 44% |
| Nov 24, 2020 | Goldman Sachs | initiate | — → Neutral | $4.75 | 54% |
| Sep 9, 2020 | SVB Leerink | maintain | — → Outperform | $7 | — |
| May 14, 2020 | SVB Leerink | maintain | — → Outperform | $9 | — |
Price Target Trend
Apr 24, 2026 Oct 27, 2026
EPS Estimates
0y —
+1q —
0q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days